AI assistant
Adaptimmune Therapeutics PLC — Director's Dealing 2020
Aug 5, 2020
34721_dirs_2020-08-04_75d98cab-e363-4fca-8219-8c7181f9ae78.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Adaptimmune Therapeutics PLC (ADAP)
CIK: 0001621227
Period of Report: 2020-08-03
Reporting Person: TAYTON-MARTIN HELEN KATRINA (Chief Business Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2020-08-03 | American Depositary Shares | S | 200000 | $8.7409 | Disposed | 0 | Direct |
Footnotes
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 28, 2019.
F2: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $8.50 to $9.34, inclusive. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote.
F3: The ADSs reported in this Column 4 represent solely those ADSs that were sold pursuant to a Rule 10b5-1 trading plan. Additionally, the reporting person holds 15,000 ordinary shares and share options covering an aggregate of 10,159,144 ordinary shares of the Issuer.